摘要
英利昔单抗是一种肿瘤坏死因子-α的人鼠嵌合型单克隆抗体,可以抑制肿瘤坏死因子-α和可溶性受体及膜型受体的结合,使肿瘤坏死因子-α失去活性,临床可用于治疗肿瘤坏死因子-α参与的多种疾病.英利昔在治疗强直性脊柱炎,类风湿性关节炎等疾病的同时,可以引起皮肤感染、银屑病、红斑狼疮、特应性皮炎及皮肤肿瘤等皮肤疾病的发生.概述与英利昔治疗相关的皮肤表现,以利于临床医生及时发现皮肤疾病与药物的相关性.
Infliximab, a chimeric human-mouse anti-tumor necrosis factor （TNF）-alpha monoclonal antibody, can inhibit the binding of TNF-alpha with its soluble and membrane receptor and inactivate TNF-alpha. Clinically, it has been used to treat TNF-alpha-associated diseases. However, it may cause the development of infection, psoriasis, lupus erythematosus, atopic dermatitis and skin neoplasms during the treatment of ankylosing spondylitis, rheumatoid arthritis and other diseases. This article describes skin manifestations related to treatment with infliximab so as to remind clinicians to pay attention to the association between skin diseases and infliximab.
出处
《国际皮肤性病学杂志》
2010年第5期258-261,共4页
International Journal of Dermatology and Venereology
关键词
皮肤疾病
英利昔
肿瘤坏死因子Α
Skin diseases
Infliximab
Tumor necrosis factor-alpha
